Target intelligence / Profile preview

Influenza A virus H3N2 hemagglutinin (H3 HA) (H3 HA)

Target
H3 HA
Molecular classification
Viral surface glycoprotein, Receptor-binding protein, Class I viral fusion protein, Receptor
01

Overview

Influenza A virus H3N2 hemagglutinin (HA) is a critical surface glycoprotein that mediates viral entry by binding to sialic acid receptors on host respiratory epithelial cells (UniProt: P03437). It is the primary target for the host's immune system, specifically for B-cell receptors (BCRs) and the resulting neutralizing antibodies (nAbs) produced during infection or vaccination (PubMed: 30104441). The HA molecule is a homotrimer consisting of a globular head (HA1) and a stalk region (HA2); the head is the site of most neutralizing epitopes but is highly prone to antigenic drift (Nature: 10.1038/nature10374). This rapid evolution allows H3N2 strains to evade existing immunity, making it a major cause of seasonal influenza morbidity and mortality (CDC: Influenza Virus Genome and Proteins). Therapeutic interventions, such as seasonal vaccines, aim to elicit nAbs that block the receptor-binding site or prevent the conformational changes required for viral-host membrane fusion (Science: 10.1126/science.aam5757). Research into broadly neutralizing antibodies often targets the more conserved HA stalk to develop universal influenza vaccines (Cell: 10.1016/j.cell.2018.11.005).

Other names
H3N2 HemagglutininHemagglutinin H3HA protein (H3N2)Influenza A virus (A/Hong Kong/1/1968(H3N2)) hemagglutinin
02

Mechanism of action

Neutralization of viral entry by blocking the interaction between the hemagglutinin globular head and host cell sialic acid receptors, or by inhibiting the pH-induced conformational change in the HA stalk required for membrane fusion.

03

Biological functions

Viral attachment to host cellReceptor-mediated endocytosisMembrane fusionImmune response induction
04

Disease associations

InfectionInfluenza A (H3N2) respiratory disease
05

Safety considerations

Antigenic drift (escape mutations)Egg-adaptive mutations during vaccine manufacturingOriginal antigenic sin (immune imprinting)
06

Interacting drugs

Fluzone

6 more in the full profile.

07

Biomarkers

Hemagglutination inhibition (HAI) antibody titerMicroneutralization (MN) assay titerHA-specific memory B-cell frequency

Beyond the preview

Go deeper on Influenza A virus H3N2 hemagglutinin (H3 HA) (H3 HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A virus H3N2 hemagglutinin (H3 HA) (H3 HA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call